Delcath Systems, Inc. is on the Cruelty Free Investing use of animals list because they use animals for drug testing and clinical trials.
The following document cites that the company conducts preclinical trials on animals to assess a product’s safety profile.
Product status: “Consistent first pass removal efficiency of 98% or better in both in vitro and pre-clinical GLP animal studies.” (Page 23) Read the full document.
Delcath Systems, Inc. is a pharmaceutical and medical device company, which focuses on oncology and liver cancer therapy. It develops and commercializes Melphalan Hydrochloride for Injection, which is a proprietary product for use with the Delcath Hepatic Delivery System. It is designed to administer concentrated regional chemotherapy to the liver. The company was founded on August 5, 1988 and is headquartered in New York, NY. [Source: MarketWatch]
Company Website: http://delcath.com